Is Nilotinib available from Qilu Pharmaceutical?

It is understood that the domestic drug Nilotinib (Nilotinib) produced by Qilu Pharmaceutical Factory has been approved for marketing through the relevant policies of the State Food and Drug Administration. It is a prescription drug. The specific specifications and quantities are to be determined. Its pharmaceutical ingredients are basically the same as those of the original Nilotinib drug. Other information is not yet clear.

Nilotinib is approved in more than 122 countries for the treatment of chronic- and accelerated-phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) in adult patients who are resistant to or intolerant to at least one prior therapy, including imatinib, and in more than 110 countries for the treatment of adult patients with newly diagnosed Ph+CML in the chronic phase. The long-term effects of long-term treatment with nilotinib in pediatric patients are unknown. Compared with oral solution (pH 1.2 to 1.3), the relative bioavailability of nilotinib capsules is approximately 50%, the peak concentration of nilotinib is reached 3 hours after oral administration, and nilotinib is a substrate of P-gp in vitro.

The original drug Nilotinib is marketed in China under the name Nilotinib and is covered by medical insurance, but reimbursement is limited to patients who meet the indications. SpecificationsThe price of 150mg*120 tablets per box may be around 9,000 yuan. The Indian version of Nilotinib is available overseas. The price of Nilotinib's original drug, 150mg*28 capsules per box, may be around RMB 1,000 (the price may fluctuate due to exchange rates). The ingredients of the original drug sold domestically and abroad are basically the same. Currently, there is no generic version of Nilotinib produced and launched. For more drug information and specific prices, please consult Yaode Medical Consultants.